MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
3.985
+0.138
+3.60%
After Hours: 3.511 -0.474 -11.89% 18:29 07/26 EDT
OPEN
3.950
PREV CLOSE
3.847
HIGH
4.065
LOW
3.550
VOLUME
88.82K
TURNOVER
0
52 WEEK HIGH
29.07
52 WEEK LOW
3.350
MARKET CAP
2.03M
P/E (TTM)
-0.1192
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHIO last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at PHIO last week (0708-0712)?
Weekly Report · 07/15 10:06
Phio Pharmaceuticals Announces Exercise Of Warrants For $3.1M Gross Proceeds
Phio Pharmaceuticals Corp. Has entered into definitive agreements to exercise certain outstanding warrants to purchase up to 545,286 shares of common stock. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.1 million. The company's proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells.
Benzinga · 07/12 12:03
Weekly Report: what happened at PHIO last week (0701-0705)?
Weekly Report · 07/08 10:07
BUZZ-U.S. STOCKS ON THE MOVE-Golar LNG, gold miners, Big Tech
Dow and S&P 500 struggle for direction after mixed payrolls data. Golar LNG up 6.5% on 20-year deal in Argentina. Apple up 1.7% after report of strong sales in second quarter. Gold miners rise as gold prices rise. Big Tech stocks rise.
Reuters · 07/05 16:14
BUZZ-Phio Pharma falls on ending share purchase agreement with Triton Funds
Shares of biotech co Phio Pharmaceuticals fall 8.8% to $4.77. Company terminated share purchase agreement with Triton Funds LP on July 3. Co could have purchased up to 18.8 per cent of co's stock. Co's stock down 91.5 per cent YTD.
Reuters · 07/05 13:57
Phio Pharmaceuticals Scraps Share Sale to Triton Funds
TipRanks · 07/05 12:45
Phio Pharmaceuticals terminates share purchase agreement with Triton Funds
Healthcare Phio Pharmaceuticals terminates share purchase agreement with Triton Funds LP. The company has terminated its agreement to purchase up to 18.8% of the company's common stock. Phio pharmaceuticals Corp. (PHIO) stock is down 2.7% in the last week.
Seeking Alpha · 07/05 12:38
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.